PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
News|Articles|September 8, 2014
University of Toronto Announces Collaboration with Janssen and Johnson & Johnson Innovation
Author(s)Pharmaceutical Technology Editors
Three-year agreement will support research on treatments for major brain disorders in Neuroscience Catalyst project.
Advertisement
The University of Toronto announced on Sept. 8, 2014 a open innovation collaboration with Janssen facilitated by the J&J Innovation center of California that will support research through the Collaborative Center for Drug Research (CCDR). The three-year agreement will help identify and validate new therapeutic targets that could advance clinical treatment for major brain disorders, including mood disorders and Alzheimer’s disease.
The partnership is intended to enhance discovery and exploration in the field of neuroscience and mental health. Under the terms of the agreement, the CCDR will issue three calls for proposals over three years. Collaborative and open-source research projects will be solicited from researchers at the University of Toronto and its affiliated hospitals through the Toronto Academic Health Science Network. Scientists from Janssen will work with university researchers to provide the drug discovery expertise required to rapidly develop new medicines from basic science innovations.
Source:
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement